Adalat

1. Front Matter

   Pages I-XVI

   PDF

2. Adalat: Historical Aspects from the Cardiologist’s View

   1. Adalat: Historical Aspects from the Cardiologist’s View

      • P. R. Lichtlen

      Pages 1-3

3. The History of Nifedipine in Japan

   1. The History of Nifedipine in Japan

      • S. Hosoda

      Pages 5-6

4. History of Adalat

   1. Front Matter

      Pages 7-7

      PDF

   2. The Story of Nifedipine

      • S. Kazda

      Pages 9-26

   3. Nifedipine: A Pleiotropic Vascular Drug

      • P. D. Henry

      Pages 27-31

   4. Adalat® — From the Marketing Viewpoint

      • F.-J. Bohle, G. Wiech

      Pages 33-38

   5. Economic Aspects of the Treatment of Cardiovascular Diseases with Emphasis on Angina Pectoris

      • P. G. Hugenholtz, C. van Halem, F. J. van Dalen, M. van den Brand

      Pages 39-54

5. Fundamentals of Adalat

   1. Front Matter

      Pages 55-56

      PDF

   2. Synopsis of the Most Important Biopharmaceutical Facts About Nifedipine/Adalat

      • P.-J. Schattenberg

      Pages 57-71

6. Lectures

   1. Front Matter

      Pages 73-73

      PDF

   2. Hypertension

      1. Treatment of Hypertension and Prevention of Cardiovascular Morbidity and Mortality

         • G. Mancia

         Pages 75-82

      2. Long-Term Studies on Regression of Left Ventricular Hypertrophy

         • I.-W. Franz, R. Ketelhut, U. Behr, U. Tönnesmann

         Pages 83-95

      3. Impaired Left Ventricular Function During Exercise in Hypertensive Patients with Normal Coronary Arteriograms: Effects of Nifedipine

         • I.-W. Franz, U. Tönnesmann, D. Erb, R. Ketelhut

         Pages 96-102

      4. Long-Term Reduction in Sodium Balance: Possible Additional Mechanism Whereby Nifedipine Lowers Blood Pressure

         • J. B. Pevahouse, N. D. Markandu, F. P. Cappuccio, M. G. Buckley, G. A. Sagnella, G. A. MacGregor

         Pages 103-112

      5. The Hypertensive Diabetic Patient

         • J. H. Fuller

         Pages 113-116

      6. The Epidemiology and Treatment of Hypertension in the Elderly

         • M. Fujishima, K. Ueda, Y. Hasuo, Y. Kiyohara, I. Abe

         Pages 117-126

   3. Coronary Heart Disease

      1. Myocardial Ischaemia: An Overview

         • W. G. Nayler, Xin Hua Gu, M. J. Daly, S. L. Brittnell

         Pages 129-138

      2. Variations in Ischemic Threshold During Daily Activities

         • D. Tzivoni, J. Benhorin, A. Gavish, S. Stern

         Pages 139-144

      3. Silent Ischaemia: Pathophysiological, Prognostic and Therapeutic Indicators in Chronic Stable Angina

         • K. M. Fox, D. Mulcahy

         Pages 145-150

As little as 30 years ago, cardiovascular research at Bayer was just a small sideline with in an environment dominated by chemotherapy research, and only 15 years ago, Bayer's pharmaceutical business was confined to European and Latin Ameri­ can countries, with sales in cardiovascular pharmaceuticals close to zero. It goes without saying that Adalat has changed the company as a whole in its research, development, and marketing, both in Germany and, most importantly, world­ wide. In research and development, Adalat has led the way in to new areas such as hypertension, acute neurology, dementia, atherosclerosis, and heart failure. In pharmacology, Adalat was present at the dawning of the second phar­ macological revolution, which started out from whole animal models and progres­ sed, via in vitro screening and pharmacological research on the DHP receptor, down to the molecular level with the cloning of calcium-channel proteins. Having followed the Adalat story closely in its early years as a bench scientist, let me take this opportunity to thank the inventors, the scientists, and the investigators who have helped to tap the broad potential of calcium-channel blockade with dihyd­ ropyridines in general and Adalat in particular. But, success should not obscure our vision. There is no reason for us to rest on our laurels: it will take true innovations in cardiovascular research to top the gold standard set by Adalat. Let us take up the challenge.

• Dementia
• Kalziumantagonist
• Kalziumblocker
• angina pectoris
• artery
• atherosclerosis
• blood pressure
• cardiovascular
• coronary artery disease
• coronary heart disease
• heart
• heart disease
• heart failure
• hypertension
• vascular disease

• Abtl. Innere Medizin/Kardiologie, Medizinische Hochschule Hannover, Hannover 61, Germany

  P. R. Lichtlen

• Cardiologia Policlinico, Roma, Italy

  A. Reale

Policies and ethics